Boehringer Ingelheim launches RenuTend™: a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses
It takes years of diligent training as well as a trusting relationship between horse and rider to reach their full potential as a team. That’s why a tendon or ligament injury can be devastating for horse owners, riders and trainers. For equine athletes, the diagnosis may mean many months of treatment and rehabilitation with an unknown outcome, and potential for long term impact on their ability to perform.
Boehringer Ingelheim has now received approval in Europe for RenuTend™, the first product licensed to improve healing of tendon and suspensory ligament injuries in horses. RenuTend™ is administered by intralesional injection and complements Boehringer Ingelheim’s other equine stem cell product Arti-Cell® FORTE, which is authorised to treat mild to moderate recurrent lameness associated with non-septic joint inflammation in horses.
“We are delighted to add RenuTend™ to our portfolio of stem cell products for horses, offering veterinarians a new therapeutic option for treating tendon and suspensory ligament injuries. This product demonstrates the company's commitment to bringing innovation to improve the lives of horses and the people who love them,” comments Liz Barrett, Head of Global Strategic Marketing, Equine at Boehringer Ingelheim. “RenuTend™ will allow more riders, owners and trainers to reimagine the dreams a tendon injury jeopardizes, by optimizing the possibilities for their horse to return to work with reduced potential for reinjury.”
Tendon and ligament lesions don’t always heal properly, as scar tissue can be less elastic than healthy tissue, and reinjury rates can be up to 80 percent. This can mean the end of a career for many horses. RenuTend™ is a targeted stem cell treatment with proven efficacy and repeatable results. It improves the quality of tendon healing by promoting parallel alignment of the right type of fibres and decreases the amount of scar tissue formed.
RenuTend™ will be available across the European Union. The approval for Great Britain is still pending.
Please click on the link for ‘Notes to Editors’ and ‘References’:
https://www.boehringer-ingelheim.com/animal-health/companion-animals/horses/stem-cell-therapy-tendon-and-ligament-injuries-horses
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005467/en/
Contact information
Boehringer Ingelheim Animal Health Communication
Marisa Lehn
552 16 Ingelheim, Germany
Phone: +49 6132 77 171241
Email: press@boehringer-ingelheim.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GridBeyond Closes €52M Series C Funding Round to Continue Its Platform Evolution and Invest in New & Existing Markets16.4.2024 06:00:00 CEST | Press release
GridBeyond, the leading intelligent energy and smart grid platform provider for distributed energy resource management, has closed its €52M Series C financing round. The round was led by Alantra’s Energy Transition Fund, Klima. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415760197/en/ GridBeyond closes €52M Series C funding round to continue its platform evolution and invest in new & existing markets. (Graphic: Business Wire) The Series C round also included new investors Energy Impact Partners, Mirova, ABB, Constellation and Yokogawa Electric Corporation as well as investment from existing investor, Act Venture Capital. Since its foundation in 2010, GridBeyond has been developing its AI platform to help businesses unlock the full potential of energy assets, ensuring the sustainability, resilience, and affordability of energy as the world moves towards a zero-carbon future. GridBeyond’s technology unleashes the latent
Westinghouse Congratulates Energoatom on Start of AP1000 ® Work at Khmelnytskyi NPP15.4.2024 23:17:00 CEST | Press release
Westinghouse Electric Company congratulates Energoatom, the state-owned nuclear utility of Ukraine, on the start of AP1000® activities at Khmelnytskyi Unit 5 in Ukraine. This is a critical first step in advancing the commitment made by both companies under the Memorandum of Understanding signed in 2022 for the deployment of nine AP1000 reactors in Ukraine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415282247/en/ Westinghouse Electric Company congratulates Energoatom on the start of AP1000® activities at Khmelnytskyi Unit 5 in Ukraine. (Photo: Business Wire) Today’s news follows the arrival of the first batch of Westinghouse VVER-1000 nuclear fuel for the two operating units at the Khmelnytskyi Nuclear Power Plant in March 2024. The VVER-1000 fuel was manufactured at Westinghouse’s fuel fabrication facility in Sweden, which also delivered the first batch of VVER-440 nuclear fuel to Ukraine’s Rivne Nuclear Power Plant i
World Famous Soccer Star Neymar Junior Joins Forces With Fun Brands and Enters the Cocktails and Mocktails Business With His Own Brand15.4.2024 18:00:00 CEST | Press release
Neymar da Silva Santos Júnior, known as one of the best soccer players in the world, joins forces with Fun Brands, a Miami, Florida-based beverage company, to announce a new collaborative venture of innovative, all-natural spirit- and wine-based cocktails and zero alcohol mocktails launching in Brazil later this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415201897/en/ World Famous Soccer Star Neymar Junior Announces Collaborative Venture With Fun Brands to Enter Cocktail and Mocktail Business With Own Brand (Photo: Business Wire) “This is a great opportunity for me to celebrate in a new way with my fans worldwide, creating possibilities for connection beyond soccer, which is my life,” highlighted the All-star. “I want to share the flavors of Brazil that I love the most with my soccer fans at home and around the world in a different and irreverent way. The idea of also offering non-alcoholic beverages greatly att
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome15.4.2024 15:15:00 CEST | Press release
On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored study, “Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)”, a prospective observational study evaluating the real-world impact of mogamulizumab on disease symptoms and health-related quality of life (HRQoL) in patients with these subtypes of cutaneous T-cell lymphoma (CTCL). CTCL is a rare form of non-Hodgkin lymphoma that most prominently affects the skin, presenting as patches, plaques, tumours, or reddening of the entire skin, and may be associated with severe itching. In a proportion of cases, the disease may spread to the lymph nodes, blood, and/or other organs. In the current interim analysis, symptom scores (mean) were reported for 20 adult patients with relapsed or refractory disease (8 MF; 12 SS) over their first 16 weeks of mogamulizumab
Brightcove Introduces Smart TV SDKs for Roku, Samsung, and LG Devices, Empowering Media Companies to Reach New Audiences15.4.2024 15:00:00 CEST | Press release
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today announced the launch of its new player platforms for Roku, Samsung and LG Smart TVs. The launch of the new Software Development Kits (SDKs) has unlocked advanced features within Brightcove’s industry-leading player framework, including content protection, monetization, and analytics reporting capabilities. Designed to reduce the cost and speed of high-quality app development, media companies can more effectively target the Smart TV platforms fueling media growth while delivering a consistent, engaging premium viewer experience. “Brightcove is committed to helping media companies deliver engaging and world-class reliable streaming experiences while reducing the costs traditionally associated with launching and running an OTT service," said Scott Levine, Chief Product Officer at Brightcove. “Our comprehensive platform enables media companies to benefit from out-of-the-box functionality and deliver pre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom